Gold prices just lower; monthly gains on track
Vaxart Inc. (VXRT), a biotechnology company focused on developing oral recombinant vaccines, saw its stock price touch a 52-week low of $0.31, reflecting a period of significant pressure for the company. With a market capitalization of just $73 million and an overall Financial Health Score of "FAIR" according to InvestingPro, the company faces notable challenges. This latest price level underscores a challenging year for Vaxart, which has experienced a stark decline in its market valuation. Over the past year, the company, previously known as Nabi Pharmaceuticals (NASDAQ:VXRT), has witnessed its stock price plummet by an alarming 70.96%. Technical indicators suggest the stock is currently in oversold territory, while rapidly depleting cash reserves present additional concerns. This substantial drop highlights the hurdles faced by the firm, including investor skepticism about the commercial viability of its vaccine candidates and the broader market trends that have impacted the biotech sector as a whole. For deeper insights into Vaxart's financial health and growth prospects, investors can access comprehensive analysis through InvestingPro's detailed research reports.
In other recent news, Vaxart Inc. reported its fourth quarter 2024 earnings, revealing a significant miss on earnings per share (EPS) but a notable beat on revenue. The EPS came in at -$0.33, falling short of the forecasted -$0.10, while revenue reached $28.7 million, surpassing expectations of $20.77 million. Despite the earnings miss, Vaxart maintains a cash runway into the fourth quarter of 2025, supporting its ongoing vaccine development programs. The company continues to advance its norovirus and other vaccine projects, with top-line data from its norovirus Phase 1 trial expected by mid-2025. Additionally, Vaxart is addressing the impact of a stop work order from BARDA related to its COVID-19 program, while exploring partnership and non-dilutive funding options. The company's strategic focus remains on developing next-generation oral vaccines, with promising advancements in its norovirus vaccine candidate. Vaxart's recent developments underscore its commitment to innovative vaccine solutions despite financial challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.